HALO

HALO

USD

Halozyme Therapeutics Inc. Common Stock

$68.050+0.410 (0.606%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$67.640

Haut

$69.910

Bas

$65.000

Volume

0.89M

Fondamentaux de l'Entreprise

Capitalisation Boursière

8.0B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

2.09M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $42.01Actuel $68.050Haut $79.5

Actualités Connexes

Analyst Upgrades

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $65

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics with a Neutral and raises the price target from $63 to $65.

Voir plus
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $65
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics with a Buy and maintains $90 price target.

Voir plus
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target
Analyst Upgrades

Leerink Partners Upgrades Halozyme Therapeutics to Market Perform, Announces $70 Price Target

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics from Underperform to Market Perform and announces $70 price target.

Voir plus
Leerink Partners Upgrades Halozyme Therapeutics to Market Perform, Announces $70 Price Target